Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin

Metabolic Engineering

Volumn 14, Issue 2, 2012, Pages 81-90

  Baik, Jong Youn ^a   Gasimli, Leyla ^b   Yang, Bo ^c   Datta, Payel ^b   Zhang, Fuming ^d   Glass, Charles A ^e   Esko, Jeffrey D ^e   Linhardt, Robert J ^b,c,d   Sharfstein, Susan T ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c Rensselaer Polytechnic Institute   (United States)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulant; Chinese hamster ovary cells; Flow cytometry; Heparin; LC MS

Indexed keywords

ANTICOAGULANT; ANTICOAGULANT ACTIVITIES; ANTITHROMBIN III; BINDING ASSAYS; BIOPHARMACEUTICAL INDUSTRY; BIOSYNTHETIC PATHWAY; BLOOD COAGULATION; CELL LINES; CHINESE HAMSTER OVARY CELLS; CHO CELL; ENDOGENOUS ENZYME; EXPRESSION LEVELS; HEALTH CRISIS; HEPARAN SULFATES; HEPARIN; HOST CELLS; LC-MS; MAMMALIAN HOSTS; MODERN MEDICINE; PHARMACEUTICAL PROTEIN; QUANTITATIVE RT-PCR; STRUCTURE CHARACTERISTIC; SUSPENSION CULTURES; TRANS-GENES; TRANSFECTANTS; WESTERN BLOTTING;

BIOCHEMISTRY; BIOSYNTHESIS; CELL CULTURE; CELLS; CLONING; ENZYMES; FLOW CYTOMETRY; GENES; HYDRAULIC STRUCTURES; MAMMALS; METABOLIC ENGINEERING; SUGARS;

POLYSACCHARIDES;

ANTITHROMBIN III; ENZYME; HEPARAN SULFATE 3 O SULFOTRANSFERASE 1; HEPARIN; N DEACETYLASE N SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; CHO CELL; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; IN VITRO STUDY; METABOLIC ENGINEERING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMIDOHYDROLASES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION; HEPARIN; HUMANS; METABOLIC ENGINEERING; MICE; SULFOTRANSFERASES; TRANSFECTION; TRANSGENES;

ANIMALIA; CRICETULUS GRISEUS; MAMMALIA;

EID: 84862813597     PISSN: 10967176     EISSN: 10967184     Source Type: Journal    
DOI: 10.1016/j.ymben.2012.01.008     Document Type: Article

References (56)

1. Ahn W.S., Antoniewicz M.R. Metabolic flux analysis of CHO cells at growth and non-growth phases using isotopic tracers and mass spectrometry. Metab. Eng. 2011, 13:598-609.
2. Ahsan A., Jeske W., Hoppensteadt D., Lormeau J.C., Wolf H., Fareed J. Molecular profiling and weight determination of heparins and depolymerized heparins. J. Pharm. Sci. 1995, 84:724-727.
3. Aldor I.S., Keasling J.D. Process design for microbial plastic factories: metabolic engineering of polyhydroxyalkanoates. Curr. Opin. Biotechnol. 2003, 14:475-483.
4. Alper H., Fischer C., Nevoigt E., Stephanopoulos G. Tuning genetic control through promoter engineering. Proc. Natl. Acad. Sci. U S A 2005, 102:12678-12683.
5. Bai X., Esko J.D. An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J. Biol. Chem. 1996, 271:17711-17717.
6. Bai X., Wei G., Sinha A., Esko J.D. Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. J. Biol. Chem. 1999, 274:13017-13024.
7. Bame K.J., Esko J.D. Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J. Biol. Chem. 1989, 264:8059-8065.
8. Bartlett A.H., Hayashida K., Park P.W. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol. Cells 2007, 24:153-166.
9. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
10. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
11. Busse M., Feta A., Presto J., Wilen M., Gronning M., Kjellen L., Kusche-Gullberg M. Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. J. Biol. Chem. 2007, 282:32802-32810.
12. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002, 41:391-412.
13. Casu B. Structure and biological activity of heparin. Adv. Carbohydr. Chem. Biochem. 1985, 43:51-134.
14. Chen J., Avci F.Y., Munoz E.M., McDowell L.M., Chen M., Pedersen L.C., Zhang L., Linhardt R.J., Liu J. Enzymatic redesigning of biologically active heparan sulfate. J. Biol. Chem. 2005, 280:42817-42825.
15. Duncan M.B., Chen J., Krise J.P., Liu J. The biosynthesis of anticoagulant heparan sulfate by the heparan sulfate 3-O-sulfotransferase isoform 5. Biochim. Biophys. Acta 2004, 1671:34-43.
16. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71:435-471.
17. Forsberg E., Pejler G., Ringvall M., Lunderius C., Tomasini-Johansson B., Kusche-Gullberg M., Eriksson I., Ledin J., Hellman L., Kjellen L. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999, 400:773-776.
18. Fuster M.M., Wang L. Endothelial heparan sulfate in angiogenesis. Prog. Mol. Biol. Transl. Sci. 2010, 93:179-212.
19. Godavarti R., Davis M., Venkataraman G., Cooney C., Langer R., Sasisekharan R. Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem. Biophys. Res. Commun. 1996, 225:751-758.
20. Goh J.S., Zhang P., Chan K.F., Lee M.M., Lim S.F., Song Z. RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of normal GnT I in these mutants enhances sialylation of recombinant erythropoietin. Metab. Eng. 2010, 12:360-368.
21. Green E.M. Fermentative production of butanol-the industrial perspective. Curr. Opin. Biotechnol. 2011, 22:337-343.
22. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
23. Gustafson G.T., Pihl E. Staining of mast cell acid glycosaminoglycans in ultrathin sections by ruthenium red. Nature 1967, 216:697-698.
24. Hacker U., Nybakken K., Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 2005, 6:530-541.
25. Kuberan B., Lech M.Z., Beeler D.L., Wu Z.L., Rosenberg R.D. Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat. Biotechnol. 2003, 21:1343-1346.
26. Linhardt R.J., Dordick J.S., Deangelis P.L., Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin. Thromb. Hemost. 2007, 33:453-465.
27. Marcum J.A., Rosenberg R.D. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin. Thromb. Hemost. 1987, 13:464-474.
28. Martin J.G., Gupta M., Xu Y., Akella S., Liu J., Dordick J.S., Linhardt R.J. Toward an artificial Golgi: redesigning the biological activities of heparan sulfate on a digital microfluidic chip. J. Am. Chem. Soc. 2009, 131:11041-11048.
29. Martin V.J., Pitera D.J., Withers S.T., Newman J.D., Keasling J.D. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol. 2003, 21:796-802.
30. Martynova M.G., Bystrova O.A., Moiseeva O.M., Evdonin A.L., Kondratov K.A., Medvedeva N.D. The presence of ANP in rat peritoneal mast cells. Cell Res. 2005, 15:811-816.
31. Michalodimitrakis K., Isalan M. Engineering prokaryotic gene circuits. FEMS Microb. Rev. 2009, 33:27-37.
32. Muszbek L., Bereczky Z., Kovacs B., Komaromi I. Antithrombin deficiency and its laboratory diagnosis. Clin. Chem. Lab. Med. 2010, 48(Suppl. 1):S67-78.
33. Nairn A.V., Kinoshita-Toyoda A., Toyoda H., Xie J., Harris K., Dalton S., Kulik M., Pierce J.M., Toida T., Moremen K.W., Linhardt R.J. Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J. Proteome Res. 2007, 6:4374-4387.
34. Nemeth A., Rohlich P. Rapid separation of rat peritoneal mast cells with Percoll. Eur. J. Cell Biol. 1980, 20:272-275.
35. Nolan R.P., Lee K. Dynamic model of CHO cell metabolism. Metab. Eng. 2011, 13:108-124.
36. Noti C., Seeberger P.H. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans. Chem. Biol. 2005, 12:731-756.
37. Pan J., Qian Y., Zhou X., Pazandak A., Frazier S.B., Weiser P., Lu H., Zhang L. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat. Biotechnol. 2010, 28:203-207. (author reply 207-211).
38. Pfeifer B.A., Admiraal S.J., Gramajo H., Cane D.E., Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science 2001, 291:1790-1792.
39. Pitera D.J., Paddon C.J., Newman J.D., Keasling J.D. Balancing a heterologous mevalonate pathway for improved isoprenoid production in Escherichia coli. Metab. Eng. 2007, 9:193-207.
40. Robinson H.C., Horner A.A., Hook M., Ogren S., Lindahl U. A proteoglycan form of heparin and its degradation to single-chain molecules. J. Biol. Chem. 1978, 253:6687-6693.
41. Shaya D., Tocilj A., Li Y., Myette J., Venkataraman G., Sasisekharan R., Cygler M. Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product. J. Biol. Chem. 2006, 281:15525-15535.
42. Spear P.G., Shieh M.T., Herold B.C., WuDunn D., Koshy T.I. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv. Exp. Med. Biol. 1992, 313:341-353.
43. Sugahara K., Kitagawa H. Heparin and heparan sulfate biosynthesis. IUBMB Life 2002, 54:163-175.
44. Tumova S., Woods A., Couchman J.R. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. 2000, 32:269-288.
45. Wang L., Fuster M., Sriramarao P., Esko J.D. Endothelial heparan sulfate deficiency impairs l-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 2005, 6:902-910.
46. Wang Z., Ly M., Zhang F., Zhong W., Suen A., Hickey A.M., Dordick J.S., Linhardt R.J. E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol. Bioeng. 2010, 107:964-973.
47. Xu D., Moon A.F., Song D., Pedersen L.C., Liu J. Engineering sulfotransferases to modify heparan sulfate. Nat. Chem. Biol. 2008, 4:200-202.
48. Yamaguchi Y., Inatani M., Matsumoto Y., Ogawa J., Irie F. Roles of heparan sulfate in mammalian brain development current views based on the findings from Ext1 conditional knockout studies. Prog. Mol. Biol. Transl. Sci. 2010, 93:133-152.
49. Yang B., Weyers A., Baik J.Y., Sterner E., Sharfstein S., Mousa S.A., Zhang F., Dordick J.S., Linhardt R.J. Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal. Biochem. 2011, 415:59-66.
50. Yoshida E., Arakawa S., Matsunaga T., Toriumi S., Tokuyama S., Morikawa K., Tahara Y. Cloning, sequencing, and expression of the gene from bacillus circulans that codes for a heparinase that degrades both heparin and heparan sulfate. Biosci. Biotechnol. Biochem. 2002, 66:1873-1879.
51. Yun C.Y., Liu S., Lim S.F., Wang T., Chung B.Y., Jiat Teo J., Chuan K.H., Soon A.S., Goh K.S., Song Z. Specific inhibition of caspase-8 and -9 in CHO cells enhances cell viability in batch and fed-batch cultures. Metab. Eng. 2007, 9:406-418.
52. Zhang L., Beeler D.L., Lawrence R., Lech M., Liu J., Davis J.C., Shriver Z., Sasisekharan R., Rosenberg R.D. 6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway. J. Biol. Chem. 2001, 276:42311-42321.
53. Zhang L., Lawrence R., Frazier B.A., Esko J.D. CHO glycosylation mutants: proteoglycans. Methods Enzymol. 2006, 416:205-221.
54. Zhang L., Lawrence R., Schwartz J.J., Bai X., Wei G., Esko J.D., Rosenberg R.D. The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate. J. Biol. Chem. 2001, 276:28806-28813.
55. Zhang Z., Xie J., Liu H., Liu J., Linhardt R.J. Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry. Anal. Chem. 2009, 81:4349-4355.
56. Zhao W., Garron M.L., Yang B., Xiao Z., Esko J.D., Cygler M., Linhardt R.J. Asparagine 405 of heparin lyase II prevents the cleavage of glycosidic linkages proximate to a 3-O-sulfoglucosamine residue. FEBS Lett. 2011, 585:2461-2466.